Amedeo Smart

Free Medical Literature Service

 

Amedeo

Colorectal Neoplasms
  Free Subscription

Articles published in
Br J Cancer
    April 2026
  1. WANG Y, Song J, Song S, Zheng S, et al
    Notch signaling governs colorectal cancer metastasis via transcriptional control of TGF-beta effectors SMAD2/SMAD3.
    Br J Cancer. 2026 Apr 14. doi: 10.1038/s41416-026-03368.
    >> Share

  2. HUISMANS MA, Gort EH, van der Heijden LT, Guven Mese SM, et al
    Safety and efficacy of lapatinib, binimetinib, and vinorelbine for RAS mutant metastatic colorectal cancer: results of the RASTRIC Phase I/II trial.
    Br J Cancer. 2026 Apr 7. doi: 10.1038/s41416-026-03398.
    >> Share

  3. RAHKOLA O, Tuomisto A, Elomaa H, Karjalainen H, et al
    Significance of tumor infiltrating granulocytes and neutrophil extracellular traps in colorectal cancer.
    Br J Cancer. 2026 Apr 7. doi: 10.1038/s41416-026-03409.
    >> Share

  4. MCSORLEY ST, Burton P, Chantler D, Johnstone M, et al
    Faecal haemoglobin-based referral and investigation prioritisation is associated with colorectal cancer-specific survival in symptomatic patients: a retrospective observational study.
    Br J Cancer. 2026 Apr 2. doi: 10.1038/s41416-026-03378.
    >> Share

  5. MARTIN S, Elomaa H, Vayrynen JP, Ahtiainen M, et al
    Tumour immune contexture and immune evasion in sporadic and Lynch syndrome-associated microsatellite unstable colorectal cancers.
    Br J Cancer. 2026;134:1019-1030.
    >> Share

  6. HUANG Q, Zhao J, Zhang Y, Zhou Y, et al
    eIF3i facilitates NELFCD translation to promote metastasis via regulating EMT and invadopodia.
    Br J Cancer. 2026;134:996-1005.
    >> Share

  7. MARTIN J, Jones DA, Ellis L, Gray E, et al
    Modelled impact of a multi-cancer early detection screening programme on the demand for diagnostics in England.
    Br J Cancer. 2026;134:1190-1197.
    >> Share

    March 2026
  8. MATSUDA K, Ugai S, Miyahara S, Yao Q, et al
    Tumor vessel phenotype in colorectal cancer microenvironment according to age at diagnosis.
    Br J Cancer. 2026 Mar 25. doi: 10.1038/s41416-026-03373.
    >> Share

  9. LI M, Li Y, Li C, Liu A, et al
    Dynamic reorganisation of intratumoural bacterial florae during colorectal cancer progression.
    Br J Cancer. 2026 Mar 6. doi: 10.1038/s41416-026-03344.
    >> Share

  10. VAN MEGESEN K, Stefan A, Kieboom M, Amico R, et al
    Targeting the DNA damage response prevents regrowth of colorectal peritoneal metastasis-derived organoids following treatment with mitomycin C.
    Br J Cancer. 2026;134:831-842.
    >> Share

  11. JIANG H, Livingston M, Room R, Kibret AA, et al
    Alcohol consumption and mortality from four alcohol-related cancers in Australia 1950-2018: a time series analysis.
    Br J Cancer. 2026;134:914-923.
    >> Share

    February 2026
  12. REE AH, Bousquet PA, Visnovska T, Luders T, et al
    Exploratory biomarkers for oxaliplatin-induced nivolumab responsiveness in metastatic microsatellite-stable colorectal cancer.
    Br J Cancer. 2026 Feb 23. doi: 10.1038/s41416-026-03357.
    >> Share

  13. AIJALA VK, Harkonen J, Sirnio P, Mantere T, et al
    Urothelium marker UPK2 identifies aggressive colorectal cancers with distinct molecular and histological features.
    Br J Cancer. 2026;134:650-661.
    >> Share

  14. SOLE L, Canton E, Maqueda M, Lobo-Jarne T, et al
    ColoStem, a core oncofetal signature that identifies poor prognosis colorectal tumors.
    Br J Cancer. 2026;134:638-649.
    >> Share

    January 2026
  15. RONG Z, Xing J, Wu L, Zheng K, et al
    ULK1 promotes oxaliplatin resistance of colon cancer via phosphorylation of Bax S184.
    Br J Cancer. 2026 Jan 13. doi: 10.1038/s41416-025-03223.
    >> Share

  16. GWENZI T, Weber ANR, Trares K, Vlaski T, et al
    Effects of personalized vitamin D(3) on inflammation in colorectal cancer patients: a randomized trial.
    Br J Cancer. 2026 Jan 8. doi: 10.1038/s41416-025-03333.
    >> Share

  17. ZHANG X, Jin M, Chu Y, Liu F, et al
    STK32C activated IL-6/JAK2/STAT3 signaling and promoted tumor angiogenesis.
    Br J Cancer. 2026;134:60-71.
    >> Share

  18. BOWDEN SJ, Ellis LB, Cuming T, Brogden D, et al
    Multizonal intraepithelial neoplasia of the lower genital tract and anus in women: terminology for defining the disease, an introduction by the British Society for Colposcopy and Cervical Pathology (BSCCP), International Anal Neoplasia Society (IANS),
    Br J Cancer. 2026;134:177-184.
    >> Share

    December 2025
  19. LASKAR RS, Murphy N, Ferrari P, Brennan P, et al
    A prospective investigation of early-onset colorectal cancer risk factors-pooled analysis of three large-scale European cohorts.
    Br J Cancer. 2025 Dec 20. doi: 10.1038/s41416-025-03303.
    >> Share

  20. DENG JW, Zhou YL, Zhang YX, Zhou CB, et al
    The relationship between gut microbiota, lifestyle habits, and early-onset colorectal cancer: shedding light on early prediction.
    Br J Cancer. 2025 Dec 9. doi: 10.1038/s41416-025-03277.
    >> Share

  21. MATSUBARA Y, Bando H, Nakamura Y, Misumi T, et al
    Survival outcomes of ERBB2-amplified metastatic colorectal cancer treated with first-line chemotherapy.
    Br J Cancer. 2025 Dec 8. doi: 10.1038/s41416-025-03270.
    >> Share

  22. LEE HJ, Lee JH, Kang J, Kim K, et al
    Single-cell multiomic modelling of early metastatic events promoted by the extracellular matrix.
    Br J Cancer. 2025;133:1708-1719.
    >> Share

    November 2025
  23. SKARIN NORDENVALL A, Persson F, Martling A, Nordenskjold M, et al
    Risk of malignant melanoma and colorectal cancer in Birt-Hogg-Dube syndrome - a matched cohort study.
    Br J Cancer. 2025 Nov 5. doi: 10.1038/s41416-025-03258.
    >> Share

    October 2025
  24. OSTERMAN E, Syriopoulou E, Martling A, Andersson TM, et al
    Impact of socioeconomics on recurrences and survival in non-metastasized colorectal cancer.
    Br J Cancer. 2025 Oct 4. doi: 10.1038/s41416-025-03224.
    >> Share

  25. CHANG YH, Bresnahan ST, Taylor Head S, Harrison TA, et al
    Isoform-level analyses of 6 cancers uncover extensive genetic risk mechanisms undetected at the gene-level.
    Br J Cancer. 2025;133:874-885.
    >> Share

  26. THONG MSY, Doege D, Koch-Gallenkamp L, Bertram H, et al
    Fatigue in long-term cancer survivors: prevalence, associated factors, and mortality. A prospective population-based study.
    Br J Cancer. 2025;133:831-843.
    >> Share

  27. YU H, Jin S, Zeng M, Yang Z, et al
    TIGIT antibody with PVR competitive ability enhances cancer immunotherapy and capable of eliciting anti-tumour immune memory.
    Br J Cancer. 2025;133:743-755.
    >> Share

  28. HOPPENER DJ, Verheul SML, Nierop PMH, Buisman FE, et al
    The colorectal liver metastasis growth pattern phenotype is not dependent on genotype.
    Br J Cancer. 2025;133:945-955.
    >> Share

    September 2025
  29. XIE W, Luo Q, Ou Z, Liu W, et al
    An ABCC1-based risk model is effective in the diagnosis of synchronous peritoneal metastasis in advanced colorectal cancer.
    Br J Cancer. 2025 Sep 26. doi: 10.1038/s41416-025-03203.
    >> Share

  30. KAWAMURA H, Honda M, Nakayama Y, Oba K, et al
    Adverse events of postoperative adjuvant chemotherapy predict survival outcomes in locally advanced colorectal cancer: a pooled analysis of Japanese clinical trials.
    Br J Cancer. 2025 Sep 22. doi: 10.1038/s41416-025-03199.
    >> Share

  31. FENG Y, Zhu J, Ou C, Deng Z, et al
    Retraction Note: MicroRNA-145 inhibits tumour growth and metastasis in colorectal cancer by targeting fascin-1.
    Br J Cancer. 2025 Sep 19. doi: 10.1038/s41416-025-03209.
    >> Share

  32. MONTERO-CALLE A, Jimenez de Ocana S, Rejas-Gonzalez R, Benavente-Naranjo R, et al
    Deciphering the central role of TMOD2 in colorectal cancer progression and metastasis.
    Br J Cancer. 2025 Sep 17. doi: 10.1038/s41416-025-03184.
    >> Share

    August 2025
  33. BALLHAUSEN A, Morano F, Stahler A, Lonardi S, et al
    Primary tumor sidedness and negative hyperselection to modulate anti-EGFR-based maintenance strategies in patients with RAS wild-type metastatic colorectal cancer: individual patient data pooled analysis of two randomized clinical trials.
    Br J Cancer. 2025 Aug 28. doi: 10.1038/s41416-025-03164.
    >> Share

  34. BARLOW M, Messenger D, Preece R, Prowse A, et al
    The diagnostic accuracy of the faecal immunochemical test for the detection of early-onset colorectal cancer: an age-stratified analysis in South West England.
    Br J Cancer. 2025 Aug 22. doi: 10.1038/s41416-025-03154.
    >> Share

  35. ZHANG D, Yang S, Xu H, Chen Z, et al
    The novel role of DUSP4 in suppressing ferroptosis and promoting cytotoxicity of CD8(+) T cells in MSI colorectal cancer.
    Br J Cancer. 2025 Aug 22. doi: 10.1038/s41416-025-03119.
    >> Share

  36. GALMARINI CM, Zamora R, Gomez Del Campo P, Del Castillo-Izquierdo J, et al
    PROCC: a predictive score to identify KRAS wild type metastatic colorectal cancer patients who are likely to obtain survival benefit from panitumumab treatment.
    Br J Cancer. 2025 Aug 20. doi: 10.1038/s41416-025-03157.
    >> Share

  37. TOH Y, Wu L, Tu J, Liang Z, et al
    Anti-tumor activity of camptothecin analog conjugate of an RSPO4-based peptibody targeting LGR4/5/6 in preclinical models of colorectal cancer.
    Br J Cancer. 2025 Aug 18. doi: 10.1038/s41416-025-03121.
    >> Share

    July 2025
  38. SHENG Y, Yan L, Liu Q, Peng Y, et al
    The pronounced cytotoxic effects of chimeric antigen receptor T cells targeting B7-H3 in organoids and liver xenografts derived from colorectal cancer patients.
    Br J Cancer. 2025 Jul 28. doi: 10.1038/s41416-025-03114.
    >> Share

  39. YU L, Guo Q, Gu X, Wang Z, et al
    Impact of gut microbiome on radiotherapy and immunotherapy efficacy in microsatellite-stable colorectal cancer: role of propionic acid and B. fragilis.
    Br J Cancer. 2025 Jul 26. doi: 10.1038/s41416-025-03105.
    >> Share

  40. ZHANG J, Xiao Z, Lai D, Sun J, et al
    Retraction Note: miR-21, miR-17 and miR-19a induced by phosphatase of regenerating liver-3 promote the proliferation and metastasis of colon cancer.
    Br J Cancer. 2025 Jul 25. doi: 10.1038/s41416-025-03135.
    >> Share

  41. ZHANG J, Dong H, Liang L, Hu L, et al
    Targeting gut microbiota and arginase boosts MEK inhibitors' enhancement of antitumour immunity via MHC-I upregulation in colorectal cancer.
    Br J Cancer. 2025 Jul 17. doi: 10.1038/s41416-025-03106.
    >> Share

  42. SEO JW, Kim JY, Ha YJ, Tak KH, et al
    Prognostic and therapeutic value of a 23-gene risk score tailored to the molecular characteristics of mucinous colorectal cancer.
    Br J Cancer. 2025 Jul 2. doi: 10.1038/s41416-025-03104.
    >> Share

    June 2025
  43. MESA-EGUIAGARAY I, Iakovliev A, Li X, Timofeeva M, et al
    Association between methylation quantitative trait loci and colorectal cancer risk, survival and cancer recurrence.
    Br J Cancer. 2025 Jun 12. doi: 10.1038/s41416-025-03064.
    >> Share

  44. ZHONG W, Zhang Y, Wang W, Shao Z, et al
    TRIM26 deficiency potentially suppresses colorectal cancer liver metastasis through NF-kappaB-mediated M1-like tumor-associated macrophage polarization.
    Br J Cancer. 2025 Jun 9. doi: 10.1038/s41416-025-03072.
    >> Share

  45. RUBIO-CUESTA B, Carretero-Puche C, Llamas P, Sarmentero J, et al
    Co-targeting SRC overcomes resistance to BRAF inhibitors in colorectal cancer.
    Br J Cancer. 2025 Jun 6. doi: 10.1038/s41416-025-03058.
    >> Share

  46. ANDEL D, Nouwens AJ, Klaassen S, Laoukili J, et al
    Rational design of alternative treatment options for radioresistant rectal cancer using patient-derived organoids.
    Br J Cancer. 2025;132:973-981.
    >> Share

    April 2025
  47. YUAN F, Jia G, Wen W, Xu S, et al
    Blood metabolic biomarkers and colorectal cancer risk: results from large prospective cohort and Mendelian randomisation analyses.
    Br J Cancer. 2025 Apr 30. doi: 10.1038/s41416-025-02997.
    >> Share

  48. REITSAM NG, Markl B
    Stroma AReactive Invasion Front Areas (SARIFA) and the tumour immune microenvironment in colorectal cancer.
    Br J Cancer. 2025 Apr 26. doi: 10.1038/s41416-025-03034.
    >> Share

  49. LEE HJ, Park SW, Lee JH, Chang SY, et al
    Correction: Differential cellular origins of the extracellular matrix of tumor and normal tissues according to colorectal cancer subtypes.
    Br J Cancer. 2025 Apr 11. doi: 10.1038/s41416-025-02988.
    >> Share

  50. HASJIM BJ, Ostowari A, Gandawidjaja M, Mohammadi MD, et al
    De novo colorectal cancer after kidney transplantation: a systematic review and meta-analysis.
    Br J Cancer. 2025 Apr 5. doi: 10.1038/s41416-025-02994.
    >> Share

  51. ELOMAA H, Tarkiainen V, Aijala VK, Sirnio P, et al
    Associations of mucinous differentiation and mucin expression with immune cell infiltration and prognosis in colorectal adenocarcinoma.
    Br J Cancer. 2025;132:660-669.
    >> Share

    March 2025
  52. GRANCHER A, Beaussire-Trouvay L, Vernon V, Dutherage M, et al
    ctDNA variations according to treatment intensity in first-line metastatic colorectal cancer.
    Br J Cancer. 2025 Mar 15. doi: 10.1038/s41416-025-02971.
    >> Share

  53. TANG F, Zhu Y, Shen J, Yuan B, et al
    CD44(+) cells enhance pro-tumor stroma in the spatial landscape of colorectal cancer leading edge.
    Br J Cancer. 2025 Mar 12. doi: 10.1038/s41416-025-02968.
    >> Share

  54. TAPIAINEN VV, Sirnio P, Elomaa H, Karjalainen H, et al
    Stroma AReactive Invasion Front Areas (SARIFA), tumour immune microenvironment, and survival in colorectal cancer.
    Br J Cancer. 2025 Mar 7. doi: 10.1038/s41416-025-02972.
    >> Share

  55. LEE HJ, Park SW, Lee JH, Chang SY, et al
    Differential cellular origins of the extracellular matrix of tumor and normal tissues according to colorectal cancer subtypes.
    Br J Cancer. 2025 Mar 3. doi: 10.1038/s41416-025-02964.
    >> Share

    February 2025
  56. ZHANG Y, Wu D, Zhang Z, Ma J, et al
    Correction: Impact of lymph node metastasis on immune microenvironment and prognosis in colorectal cancer liver metastasis: insights from multiomics profiling.
    Br J Cancer. 2025 Feb 17. doi: 10.1038/s41416-025-02941.
    >> Share

  57. BUNDRED J, Lal N, Chan DKH, Buczacki SJA, et al
    Lymph node yield as a surrogate marker for tumour biology and prognosis in colon cancer.
    Br J Cancer. 2025 Feb 14. doi: 10.1038/s41416-025-02949.
    >> Share

  58. KATO Y, Seishima R, Hattori K, Kato H, et al
    Significance of homologous recombinant deficiency as a biomarker for drug sensitivity in colorectal cancer.
    Br J Cancer. 2025 Feb 11. doi: 10.1038/s41416-025-02950.
    >> Share

    January 2025
  59. ZHANG Y, Wu D, Zhang Z, Ma J, et al
    Impact of lymph node metastasis on immune microenvironment and prognosis in colorectal cancer liver metastasis: insights from multiomics profiling.
    Br J Cancer. 2025 Jan 3. doi: 10.1038/s41416-024-02921.
    >> Share

    December 2024
  60. LIU C, Reger M, Fan H, Wang J, et al
    Dietary intake of isoflavones and coumestrol and risk of pancreatic cancer in the prostate, lung, colorectal, and ovarian cancer screening trial.
    Br J Cancer. 2024 Dec 16. doi: 10.1038/s41416-024-02929.
    >> Share

    November 2024
  61. PRETTA A, Ziranu P, Perissinotto E, Ghelardi F, et al
    Early onset metastatic colorectal cancer patients as a distinctive clinical and molecular phenomenon.
    Br J Cancer. 2024 Nov 27. doi: 10.1038/s41416-024-02902.
    >> Share

  62. CHAN WC, Liu L, Bouras E, Zuber V, et al
    Associations of blood lipids and LDL cholesterol lowering drug-targets with colorectal cancer risk: a Mendelian randomisation study.
    Br J Cancer. 2024 Nov 23. doi: 10.1038/s41416-024-02900.
    >> Share

  63. POGHOSYAN S, Frenkel N, van den Bent L, Raats D, et al
    VEGF-C propagates 'onward' colorectal cancer metastasis from liver to lung.
    Br J Cancer. 2024 Nov 9. doi: 10.1038/s41416-024-02892.
    >> Share

  64. CAMPOS GUDINO R, Neudorf NM, Andromidas D, Lichtensztejn Z, et al
    Loss of EMI1 compromises chromosome stability and is associated with cellular transformation in colonic epithelial cell contexts.
    Br J Cancer. 2024;131:1516-1528.
    >> Share

    October 2024
  65. LI B, Yang W, Liu N, Bi D, et al
    Phase II Study of Irinotecan, Trifluridine/tipiracil (TAS-102) plus Bevacizumab as a Later-line Therapy for Patients with Metastatic Colorectal Cancer (mCRC): a prospective single-center explorative study.
    Br J Cancer. 2024 Oct 24. doi: 10.1038/s41416-024-02885.
    >> Share

  66. OGAARD N, Jensen SO, Orntoft MW, Demuth C, et al
    Circulating tumour DNA and risk of recurrence in patients with asymptomatic versus symptomatic colorectal cancer.
    Br J Cancer. 2024 Oct 10. doi: 10.1038/s41416-024-02867.
    >> Share

  67. NOH H, Lee J, Seyed Khoei N, Peruchet-Noray L, et al
    Serum bilirubin levels and risk of colorectal cancer in Korean adults: results from the Korean Genome and Epidemiology Study-Health Examinee (KoGES-HEXA) Cohort Study.
    Br J Cancer. 2024 Oct 8. doi: 10.1038/s41416-024-02847.
    >> Share

  68. SEKHAR H, Kochhar R, Carrington B, Kaye T, et al
    Pre-treatment magnetic resonance imaging in anal cancer: large-scale evaluation of mrT, mrN and novel staging parameters.
    Br J Cancer. 2024;131:1137-1146.
    >> Share

    September 2024
  69. AMODIO V, Vitiello PP, Bardelli A, Germano G, et al
    DNA repair-dependent immunogenic liabilities in colorectal cancer: opportunities from errors.
    Br J Cancer. 2024 Sep 13. doi: 10.1038/s41416-024-02848.
    >> Share

  70. BOLAND PM, Mukherjee S, Imanirad I, Vijayvergia N, et al
    TAS-102, Irinotecan, and bevacizumab in pre-treated metastatic colorectal cancer (TABAsCO), a phase II clinical trial.
    Br J Cancer. 2024 Sep 7. doi: 10.1038/s41416-024-02845.
    >> Share

  71. CHOWDHURY S, Xiu J, Ribeiro JR, Nicolaides T, et al
    Consensus molecular subtyping of metastatic colorectal cancer expands biomarker-directed therapeutic benefit for patients with CMS1 and CMS2 tumors.
    Br J Cancer. 2024 Sep 4. doi: 10.1038/s41416-024-02826.
    >> Share

    August 2024
  72. GWENZI T, Schrotz-King P, Anker SC, Schottker B, et al
    Prognostic value of post-operative iron biomarkers in colorectal cancer: population-based patient cohort.
    Br J Cancer. 2024 Aug 27. doi: 10.1038/s41416-024-02814.
    >> Share

    July 2024
  73. SEGAL NH, Tie J, Kopetz S, Ducreux M, et al
    COLUMBIA-1: a randomised study of durvalumab plus oleclumab in combination with chemotherapy and bevacizumab in metastatic microsatellite-stable colorectal cancer.
    Br J Cancer. 2024 Jul 25. doi: 10.1038/s41416-024-02796.
    >> Share

  74. LAWLER T, Hibler E, Walts ZL, Giurini L, et al
    Associations of diabetes and mortality among colorectal cancer patients from the Southern Community Cohort Study.
    Br J Cancer. 2024 Jul 19. doi: 10.1038/s41416-024-02787.
    >> Share

  75. HOU P, Shi P, Jiang T, Yin H, et al
    Correction: DKC1 enhances angiogenesis by promoting HIF-1alpha transcription and facilitates metastasis in colorectal cancer.
    Br J Cancer. 2024 Jul 17. doi: 10.1038/s41416-024-02801.
    >> Share

  76. MASUI H, Kawada K, Itatani Y, Hirai H, et al
    Synergistic antitumor activity by dual blockade of CCR1 and CXCR2 expressed on myeloid cells within the tumor microenvironment.
    Br J Cancer. 2024;131:63-76.
    >> Share

  77. TSUKADA Y, Bando H, Inamori K, Wakabayashi M, et al
    Three-year outcomes of preoperative chemoradiotherapy plus nivolumab in microsatellite stable and microsatellite instability-high locally advanced rectal cancer.
    Br J Cancer. 2024;131:283-289.
    >> Share

    June 2024
  78. YANG L, Yi J, He W, Kong P, et al
    Correction: Death receptors 4/5 mediate tumour sensitivity to natural killer cell-mediated cytotoxicity in mismatch repair deficient colorectal cancer.
    Br J Cancer. 2024 Jun 26. doi: 10.1038/s41416-024-02768.
    >> Share

  79. EXARCHAKOU A, Rachet B, Lyratzopoulos G, Maringe C, et al
    What can hospital emergency admissions prior to cancer diagnosis tell us about socio-economic inequalities in cancer diagnosis? Evidence from population-based data in England.
    Br J Cancer. 2024;130:1960-1968.
    >> Share

    May 2024
  80. YANG L, Yi J, He W, Kong P, et al
    Death receptors 4/5 mediate tumour sensitivitNot applicably to natural killer cell-mediated cytotoxicity in mismatch repair deficient colorectal cancer.
    Br J Cancer. 2024 May 25. doi: 10.1038/s41416-024-02673.
    >> Share

  81. ZWART K, van Nassau SCMW, van der Baan FH, Koopman M, et al
    Efficacy-effectiveness analysis on survival in a population-based real-world study of BRAF-mutated metastatic colorectal cancer patients treated with encorafenib-cetuximab.
    Br J Cancer. 2024 May 20. doi: 10.1038/s41416-024-02711.
    >> Share

  82. VILLAREAL LB, Falcon DM, Xie L, Xue X, et al
    Hypoxia-inducible factor 3alpha1 increases epithelial-to-mesenchymal transition and iron uptake to drive colorectal cancer liver metastasis.
    Br J Cancer. 2024 May 1. doi: 10.1038/s41416-024-02699.
    >> Share

  83. QIAO L, Liu Y, Yang Q
    Comment on: "Neoadjuvant chemotherapy is noninferior to chemoradiotherapy for early-onset locally advanced rectal cancer in the FOWARC trial".
    Br J Cancer. 2024;130:1432-1433.
    >> Share

  84. CAI J, Lin K, Luo T, Weng J, et al
    Neoadjuvant chemotherapy is noninferior to chemoradiotherapy for early-onset locally advanced rectal cancer in the FOWARC trial.
    Br J Cancer. 2024;130:1434-1440.
    >> Share

  85. MENG XN, Ma JF, Liu YH, Li SQ, et al
    Dynamic genomic changes in methotrexate-resistant human cancer cell lines beyond DHFR amplification suggest potential new targets for preventing drug resistance.
    Br J Cancer. 2024;130:1819-1827.
    >> Share

  86. KISAKOL B, Matveeva A, Salvucci M, Kel A, et al
    Identification of unique rectal cancer-specific subtypes.
    Br J Cancer. 2024;130:1809-1818.
    >> Share

    April 2024
  87. REE AH, Saltyte Benth J, Hamre HM, Kersten C, et al
    First-line oxaliplatin-based chemotherapy and nivolumab for metastatic microsatellite-stable colorectal cancer-the randomised METIMMOX trial.
    Br J Cancer. 2024 Apr 25. doi: 10.1038/s41416-024-02696.
    >> Share

  88. RIO-VILARINO A, Cenigaonandia-Campillo A, Garcia-Bautista A, Mateos-Gomez PA, et al
    Correction: Inhibition of the AURKA/YAP1 axis is a promising therapeutic option for overcoming cetuximab resistance in colorectal cancer stem cells.
    Br J Cancer. 2024 Apr 4. doi: 10.1038/s41416-024-02667.
    >> Share

  89. BARANYI M, Molnar E, Hegedus L, Gabriel Z, et al
    Farnesyl-transferase inhibitors show synergistic anticancer effects in combination with novel KRAS-G12C inhibitors.
    Br J Cancer. 2024;130:1059-1072.
    >> Share

  90. TIAN Y, Lin Y, Qu C, Arndt V, et al
    Genetic risk impacts the association of menopausal hormone therapy with colorectal cancer risk.
    Br J Cancer. 2024 Apr 1. doi: 10.1038/s41416-024-02638.
    >> Share

    March 2024
  91. FELIU J, Gamez-Pozo A, Martinez-Perez D, Perez-Wert P, et al
    Functional proteomics of colon cancer Consensus Molecular Subtypes.
    Br J Cancer. 2024 Mar 14. doi: 10.1038/s41416-024-02650.
    >> Share

  92. ZHANG X, He Y, Li X, Shraim R, et al
    Circulating 25-hydroxyvitamin D and survival outcomes of colorectal cancer: evidence from population-based prospective cohorts and Mendelian randomisation.
    Br J Cancer. 2024 Mar 13. doi: 10.1038/s41416-024-02643.
    >> Share

  93. RIO-VILARINO A, Cenigaonandia-Campillo A, Garcia-Bautista A, Mateos-Gomez PA, et al
    Inhibition of the AURKA/YAP1 axis is a promising therapeutic option for overcoming cetuximab resistance in colorectal cancer stem cells.
    Br J Cancer. 2024 Mar 11. doi: 10.1038/s41416-024-02649.
    >> Share

  94. DENG LQ, Shi CJ, Zhou ST, Zeng WQ, et al
    EIF4A3-negatively driven circular RNA beta-catenin (circbeta-catenin) promotes colorectal cancer progression via miR-197-3p/CTNND1 regulatory axis.
    Br J Cancer. 2024 Mar 8. doi: 10.1038/s41416-024-02612.
    >> Share

  95. GOURIOU C, Lemanski C, Pommier P, Le Malicot K, et al
    Management of non-metastatic anal cancer in the elderly: ancillary study of the French multicenter prospective cohort FFCD-ANABASE.
    Br J Cancer. 2024;130:769-776.
    >> Share

    February 2024
  96. KARAPETIS CS, Liu H, Sorich MJ, Pederson LD, et al
    Fluoropyrimidine type, patient age, tumour sidedness and mutation status as determinants of benefit in patients with metastatic colorectal cancer treated with EGFR monoclonal antibodies: individual patient data pooled analysis of randomised trials fro
    Br J Cancer. 2024 Feb 24. doi: 10.1038/s41416-024-02604.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016